All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CX717
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CX717
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Studies describes the ability of CX717, one of the Company’s lead ampakines, to improve motor nerve function in an animal model of spinal cord injury. CX717 improved the electrical activity of the phrenic motor nerve when recorded below the site of the spinal injury.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mesenchymal Stem Cells
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: JadiCell
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Using animal models, Company collaborators demonstrated stimulation of stem cell proliferation that reside in parts of the brain called the "dentate gyrus".
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BA-1049
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BA-1049
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
The latest notice covers the critical patent application (US 16/214,973) for the proprietary method of treatment of cerebral aneurysms with BA-1049 and other ROCK2 oral drug candidates now in development.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AV-001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AV-001
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: US Department of Defense
Deal Size: $2.8 million Upfront Cash: Undisclosed
Deal Type: Funding August 18, 2020
Details:
Funding will support the development AV-001 for the treatment of COVID-19-associated acute lung injury and acute respiratory distress syndrome (ARDS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
The study used mouse model to demonstrate that calpain-2 genetic deletion or blockade with NeurAegis' novel calpain-2 inhibitor eliminated the consequences of repeated concussions and protected the brain against neuroinflammation, neurodegeneration and cognitive impairment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KB-1801
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
This research shows that the activation of P2Y14 receptors initiates the secretion of proinflammatory factors within the kidney and rapidly causes the recruitment of neutrophils and monocytes, starting the inflammatory cycle.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HST 004
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the ASCO 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): rhNELL-1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
Details:
Bone Biologics has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
